Literature DB >> 9240366

Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse.

L N Voruganti1, R J Heslegrave, A G Awad.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9240366     DOI: 10.1097/00005053-199707000-00008

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


× No keyword cloud information.
  13 in total

Review 1.  Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later.

Authors:  A George Awad
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

Review 2.  Antipsychotic medication-induced dysphoria: its meaning, association with typical vs. atypical medications and impact on adherence.

Authors:  Hanjing Emily Wu; Olaoluwa O Okusaga
Journal:  Psychiatr Q       Date:  2015-06

3.  Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders.

Authors:  Mary F Brunette; Robert E Drake; Haiyi Xie; Gregory J McHugo; Alan I Green
Journal:  Schizophr Bull       Date:  2006-06-16       Impact factor: 9.306

4.  The 2nd Schizophrenia International Research Society Conference, 10-14 April 2010, Florence, Italy: summaries of oral sessions.

Authors:  Moogeh Baharnoori; Cali Bartholomeusz; Aurelie A Boucher; Lisa Buchy; Christopher Chaddock; Bonga Chiliza; Melanie Föcking; Alex Fornito; Juan A Gallego; Hiroaki Hori; Gisele Huf; Gul A Jabbar; Shi Hyun Kang; Yousri El Kissi; Jessica Merchán-Naranjo; Gemma Modinos; Nashaat A M Abdel-Fadeel; Anna-Karin Neubeck; Hsiao Piau Ng; Gabriela Novak; Olasunmbo O Owolabi; Diana P Prata; Naren P Rao; Igor Riecansky; Darryl C Smith; Renan P Souza; Renate Thienel; Hanan D Trotman; Hiroyuki Uchida; Kristen A Woodberry; Anne O'Shea; Lynn E DeLisi
Journal:  Schizophr Res       Date:  2010-10-08       Impact factor: 4.939

Review 5.  Substance misuse in patients with schizophrenia: epidemiology and management.

Authors:  David J Kavanagh; John McGrath; John B Saunders; Glenys Dore; Dianne Clark
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 6.  Impact of atypical antipsychotics on quality of life in patients with schizophrenia.

Authors:  A George Awad; Lakshmi N P Voruganti
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 7.  Revisiting the 'self-medication' hypothesis in light of the new data linking low striatal dopamine to comorbid addictive behavior.

Authors:  A George Awad; Lakshmi L N P Voruganti
Journal:  Ther Adv Psychopharmacol       Date:  2015-06

Review 8.  Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life.

Authors:  Martin Lambert; Dieter Naber
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 9.  Psychiatric comorbidities and schizophrenia.

Authors:  Peter F Buckley; Brian J Miller; Douglas S Lehrer; David J Castle
Journal:  Schizophr Bull       Date:  2008-11-14       Impact factor: 9.306

10.  Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use Disorders.

Authors:  Sarah C Akerman; Mary F Brunette; Douglas L Noordsy; Alan I Green
Journal:  Curr Addict Rep       Date:  2014-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.